BRAF and cancer: To target upregulated mitogenic signaling in cancer, we used the KRASG12C inhibitor sotorasib, the BRAF inhibitor vemurafenib, and trametinib in KRASG12C-mutant non-small cell lung cancer (H358 and H1373), BRAFV600E-mutant melanoma (WM983B and WM989), and G protein-mutant uveal melanoma (MP41 and MP46) cell lines, respectively.